author-photo

Cheryl A. Pickett

Amgen

7

Papers

70

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB-IVM1c melanoma.

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (5)
Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma

2019 EBioMedicine
Show All
- Source
- Cite
- Save
Citations (14)
Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer

2019 Clinical Breast Cancer
Show All
- Source
- Cite
- Save
Citations (6)
A phase 1b study of Trebananib plus Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in patients with HER2+ locally recurrent or metastatic breast cancer

2015 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.

2015 The Breast
Show All
- Source
- Cite
- Save
Citations (36)